Capricor Therapeutics: Promising Advances in Duchenne Cardiomyopathy Treatment Drive Buy Rating
Maxim Group analyst Jason McCarthy maintained a Buy rating on Capricor Therapeutics (CAPR – Research Report) yesterday and set a price target ...
来自MSN13 小时
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA
Shares of Capricor Therapeutics CAPR gained 8.4% on Thursday following the completion of the submission of a biologics ...
Irish Examiner13 小时
Mother's heartfelt plea raises more than €400k for son Archie
Una Ennis has taken to social media to describe how she and her husband Keith were told their eldest child has Duchenne ...
Managed Healthcare Executive13 小时
Capricor Completes BLA for Deramiocel for Duchenne Cardiomyopathy
Deramiocel is a cell therapy that has healing effects in muscle cells. If approved, deramiocel would be a once-quarterly ...
pharmaphorum19 小时
Capricor files cell therapy for DMD cardiomyopathy with FDA
Capricor Therapeutics has completed its US marketing application for deramiocel, a cell therapy the US biotech hopes will ...
Capricor Therapeutics Completes BLA Submission for Deramiocel Treatment of Duchenne ...
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology firm specializing in innovative cell and exosome-based therapies for rare diseases, finalized the submission of its Biologics License ...
marketinference20 小时
Capricor Therapeutics Makes Progress in DMD Treatment
This milestone has triggered a $10 million milestone payment to Capricor from Nippon Shinyaku, the company's distribution ...